WO1988010113A1 - Compose, composition et procede pour la reduction des lipides, la modification de l'affinite de l'hemoglobine pour l'oxygene, et la prevention de l'agregation des plaquettes - Google Patents

Compose, composition et procede pour la reduction des lipides, la modification de l'affinite de l'hemoglobine pour l'oxygene, et la prevention de l'agregation des plaquettes Download PDF

Info

Publication number
WO1988010113A1
WO1988010113A1 PCT/US1988/002092 US8802092W WO8810113A1 WO 1988010113 A1 WO1988010113 A1 WO 1988010113A1 US 8802092 W US8802092 W US 8802092W WO 8810113 A1 WO8810113 A1 WO 8810113A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
compound
hemoglobin
straight
hydrogen
Prior art date
Application number
PCT/US1988/002092
Other languages
English (en)
Inventor
Iraj Lalezari
Samuel Rahbar
Parviz Lalezari
Original Assignee
Iraj Lalezari
Samuel Rahbar
Parviz Lalezari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iraj Lalezari, Samuel Rahbar, Parviz Lalezari filed Critical Iraj Lalezari
Publication of WO1988010113A1 publication Critical patent/WO1988010113A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the applicants have discovered a new class of phenylureido substituted phenoxy propionic acid compounds which can be administered orally to mammals to reduce total blood cholesterol levels and low density lipid-cholesterol levels without substantially affecting high density lipid- cholesterol levels.
  • the compounds may also be utilized to modify the affinity of hemoglobin for oxygen or to prevent platelet aggregation.
  • R 1 , R 2 , R 3 and R 4 may be the same or different and independently selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl of from 1-6 carbon atoms, aryl, cycloalkyl of 4 to 7 carbon atoms; and alkoxy of
  • R 5 and R 6 may be the same or different and are selected from the group consisting of hydrogen, halogen, straight and branched chain alkyl groups of from 1-6 carbon atoms, aralkyl groups wherein the alkyl portion has from 1-6 carbon atoms cycloalkyl of from 4-7 carbon atoms and aryl;
  • R 7 is hydrogen or a straight or branched chain alkyl group of 1-6 carbon atoms and the pharmaceutically acceptable salts such as the sodium, potassium, ammonium, etc.
  • the invention also includes pharmaceutical compositions that are based on a compound of Formula I and methods for the reduction of hyperlipidemia by the oral administration of a comoound of Formula I.
  • FIG. 1 shows the effects of a compound of the invention on the oxygen dissociation of human hemoglobin solution.
  • FIG. 2 shows the effects of a compound of the invention on the oxygen dissociation of intact human red blood cells.
  • the nitrophenoxy acid is prepared according to the procedure described by P. Galimberti et al., Gazz. Chim. Ital. 77,431 (1947).
  • the amino substituted compound is prepared by catalytic hydrogenation of the nitro compound according to the procedure of G.E. Wicks, Jr., J. Med. Chem. 15,436 (1972).
  • the amino substituted compound is then reacted with an arylisocyanate to form the arylureido acid compound of the invention.
  • the esters of the free acid are formed by reacting the appropriate alcohol with the free acid using conventional ester forming conditions.
  • the pharmaceutically acceptable salts may be prepared by standard procedures using the appropriate metal or ammonium salt such as sodium hydroxide, sodium bicarbonate, potassium hydroxide and the like.
  • the compounds of the invention may be administered to mammals including humans to reduce or prevent hyperlipidemia especially to reduce the levels of total serum cholesterol, low density lipoprotein-associated cholesterol and trigly- cerides.
  • the compounds may be administered orally at a daily dosage of frdm about 1 to 200 mg per kilogram of body weight and more preferably at a level of about 10 to 50 mg per kilogram of body weight.
  • the daily dosage is to be administered as a single dose, or in divided amounts three or four times a day. It is understood that the dose may be varied according to individual sensitivity and the type of hyperlipidemia being treated.
  • the compounds may be administered parenterally or rectally. The parenteral dose will be 15-25% of the oral dosage and the rectal dosage may be adjusted to obtain the desired therapeutic affect.
  • the compounds of the invention may be added to whole blood or packed cells in an amount of about 50mg to 2.0g per unit of blood (473ml) or unit of packed cells (235ml) and preferably from 250mg to 750mg per unit of blood or unit of packed cells in order to facilitate the dissociation of oxygen from hemoglobin and improve the oxygen delivery capability of blood.
  • the hemoglobin in the blood tends to increase its affinity for oxygen by losin 2,3-diphosphoglycerides.
  • the compounds of the invention are capable of reversing and/or preventing the functional abnormality of hemoglobin which is observed when whole blood or packed cells are stored.
  • the compounds of the invention may be added to whole blood or red blood cell fractions in a closed system using an appropriate resevoir in which the compound is placed prior to storage or which is present in the anticoagulating solution in the blood collecting bag.
  • the compounds may be administered to patients in whom the affinity of hemoglobin for oxygen is abnormally high (e.g. certain hemoglobinopathies), or when the availability of hemoglobin to tissues is decreased, (e.g. in ischemic conditions such as peripheral vascular disease, coronary occlusion or cerebral vascular accidents).
  • the compounds may also be used to inhibit platelet aggregation and may be used for antithrombotic purposes.
  • the dosage for the modification of the affinity of hemoglobin for oxygen may be based on the dosages set forth above for hyperlipidemia and these dosages may be adjusted for parenteral use to obtain the desired therapeutic result.
  • the compounds should not be administered to patients with sickle cell disease to avoid the possibility of excessive oxygen loss which may precipitate a sickle cell crisis.
  • halogen is used to include bromo, chloro, fluoro and iodo
  • alkyl includes straight and branched chain hydrocarbon groups of 1-6 carbon atoms such as methyl, ethyl, n-propyl, n-pentyl and the like
  • aryl includes phenyl and naphthyl
  • cycloalkyl includes cycloaliphatic groups of 4 to 7 carbon atoms such a cyclobutyl, cyclopentyl, cyclohexyl and the like
  • alkoxy is used to include R 8 OH groups wherein R 8 is alkyl of 1 to 6 carbon atoms
  • aralkyl is used to include phenalkyl groups wherein the alkyl portion is an alkylene moiety of 1-6 carbons such as benzyl, phenethyl, phenpropyl and the like.
  • pharmaceutically acceptable diluent is used to include liquid and solid materials conventionally utilized to prepare injectable dosage forms and solid dosage forms such as tablets and capsules.
  • Water may be used for the preparation of injectable compositions which may also include conventional buffers and agents to render the injectable composition isotonic
  • the solid diluents and excipients include lactose, starch, conventional disintegrating agents, coatings and the like.
  • UK patent 1,535,683 which is incorporated by reference, gives several embodiments of formulation that may be utilized in the preparation of tablets and capsules.
  • nitrophenoxy 2-methyl propionic acid intermediate was prepared by the reaction of chlorofrom with 4-nitrophenol and sodium hydroxide in dry acetone as described by P. Galimberti and A. Defranceschi, Gazz. Chim. Ital. 77, 431, (1947). The yield was 54%. mp 121-123°. (recrystallized from CCl 4 ).
  • the amino phenoxy hydrochloride compound was prepared by catalytic hydrogenation of the nitro compound as described by H. Z. Sommer and G. E. Wicks, Jr., J. Med. Chem. 15, 436 (1972).
  • the free base required for the synthesis of phenylureido derivatives was obtained by alkalinization of the hydrochloride with IN NaOH followed by the addition of concentrated acetic acid to precipitate the free acid as a crystalline compound, mp 214-216°.
  • FIG. 1 illustrates the oxygen dissociation curves produced by a 50 uM solution of normal human hemoglobin tested at pH 7.2 using TRIS as the buffer in a Hemox analyzer. In this test, percent oxygen saturation (on the vertical axis) is plotted against the partial pressure of oxygen (pO 2 in the horizontal axis).
  • Curve #1 shows the normal oxygen dissociation curve in the absence of any modifying agent.
  • Curve #2 shows a shift to the right when 5mM Bezafibrate that was solubilized with an equimolar amount of sodium bicarbonate is added.
  • Curve #3 shows the right shift caused by 1mM concentration of the compound of Example 3 that was solubilized with an equimolar amount of sodium bicarbonate and curve #4 shows the shift affected by the presence of 0.5mM of the compound of Example 3.
  • Fig. 2 illustrates the same effects when the intact human RBCs are treated with the same compounds.
  • 50 uL washed human RBCs were suspended in 4ml of HEPES buffer (pH 7.4) and oxygen dissociation curves were obtained.
  • Curve #1 shows the oxyge dissociation curve produced by Hb in untreated RBCs.
  • Curve #2 illustrates the right shift caused by the presence of 5mM Bezafibrate.
  • This example describes the cholesterol and lipoprotein reducing activities of the compounds of the invention.
  • Animals in Group one received normal rat diet.
  • Nath's diet is composed of 49% sucrose, 24% coconut oil, 18% casein, vitamin mixture 2%, Maize oil 1%, Mineral salts 4%, cholic acid 1%, and cholesterol 1%.
  • Animals in Group two received no medications and served as hyperlipemic controls.
  • Animals in Group 3 received 30 mg/kg/day of the compound of Example 3 mixed with their food. At the end of fifteen days all the animals were sacrificed and their blood cholesterol and lipids were measured. The results are as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouveaux composés de formule (I) dans laquelle R2, R2, R3 et R4 peuvent être identiques ou différents et choisis indépendamment dans le groupe composé d'un hydrogène, halogène, alkyle à chaîne droite ou ramifiée de 1 à 6 atomes de carbone, aryle, cycloalkyle de 4 à 7 atomes de carbone; et alkoxy de 1 à 6 atomes de carbone; R5 et R6 peuvent être identiques ou différents et sont choisis dans le groupe composé d'un hydrogène, halogène, de groupes alkyle à chaîne droite ou ramifiée de 1 à 6 atomes de carbone, de groupes aralkyle où la portion alkyle possède de 1 à 6 atomes de carbone, cycloalkyle de 4 à 7 atomes de carbone et aryle; R7 est hydrogène ou un groupe alkyle à chaîne droite ou ramifiée de 1 à 6 atomes de carbone. Sont également décrits leurs sels pharmaceutiquement acceptables. Ces composés sont utiles pour le traitement de l'hyperlipidémie et pour le traitement in vivo et in vitro de l'hémoglobine ou du sang en vue de modifier l'affinité de l'hémoglobine pour l'oxygène.
PCT/US1988/002092 1987-06-15 1988-06-15 Compose, composition et procede pour la reduction des lipides, la modification de l'affinite de l'hemoglobine pour l'oxygene, et la prevention de l'agregation des plaquettes WO1988010113A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6223687A 1987-06-15 1987-06-15
US062,236 1987-06-15

Publications (1)

Publication Number Publication Date
WO1988010113A1 true WO1988010113A1 (fr) 1988-12-29

Family

ID=22041101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/002092 WO1988010113A1 (fr) 1987-06-15 1988-06-15 Compose, composition et procede pour la reduction des lipides, la modification de l'affinite de l'hemoglobine pour l'oxygene, et la prevention de l'agregation des plaquettes

Country Status (4)

Country Link
EP (1) EP0358724A4 (fr)
JP (1) JPH02503797A (fr)
AU (1) AU616674B2 (fr)
WO (1) WO1988010113A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420930A1 (fr) * 1988-06-15 1991-04-10 LALEZARI, Iraj Procede de synthese et nouveaux composes destines a des utilisations pharmaceutiques
WO1991012235A1 (fr) * 1990-02-12 1991-08-22 Center For Innovative Technology Modificateurs allosteriques d'hemoglobine
US5382680A (en) * 1990-12-07 1995-01-17 The Center For Innovative Technology Allosteric hemoglobin modifier compounds
US5658944A (en) * 1990-12-12 1997-08-19 The University Of South Carolina Anti-atherosclerotic aryl compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021599A1 (fr) * 1993-03-17 1994-09-29 Meiji Seika Kabushiki Kaisha Nouveau compose a activite inhibitrice de l'agregation des plaquettes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614045A1 (de) * 1976-04-01 1977-10-06 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeuren und verfahren zur herstellung derselben

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614045A1 (de) * 1976-04-01 1977-10-06 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeuren und verfahren zur herstellung derselben

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0358724A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420930A1 (fr) * 1988-06-15 1991-04-10 LALEZARI, Iraj Procede de synthese et nouveaux composes destines a des utilisations pharmaceutiques
EP0420930A4 (en) * 1988-06-15 1991-12-04 Iraj Lalezari Method of synthesis and novel compounds for pharmaceutical uses
WO1991012235A1 (fr) * 1990-02-12 1991-08-22 Center For Innovative Technology Modificateurs allosteriques d'hemoglobine
US5049695A (en) * 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5382680A (en) * 1990-12-07 1995-01-17 The Center For Innovative Technology Allosteric hemoglobin modifier compounds
US5658944A (en) * 1990-12-12 1997-08-19 The University Of South Carolina Anti-atherosclerotic aryl compounds

Also Published As

Publication number Publication date
EP0358724A1 (fr) 1990-03-21
AU616674B2 (en) 1991-11-07
JPH02503797A (ja) 1990-11-08
EP0358724A4 (fr) 1990-06-05
AU1998688A (en) 1989-01-19

Similar Documents

Publication Publication Date Title
KR0159095B1 (ko) 벤조일구아니딘, 이의 제조방법 및 이를 함유하는 약제학적 조성물
JP3231042B2 (ja) ２−（２，６−ジ−ハロ−フェニルアミノ）フェニル酢酸の誘導体の硝酸エステルおよびその製造法
US5268500A (en) Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US4921997A (en) Method of synthesis and novel compounds for pharmaceutical uses
JPH069545A (ja) ｏ−置換ベンゾイルグアニジン、その製造方法、医薬または診断剤としてのその使用およびそれを含有する医薬
IE64603B1 (en) Antihyperlipidemic and antiatherosclerotic urea compounds
US4743611A (en) Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
AU616674B2 (en) Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation
US4925968A (en) N-acyl-N-naphthoylglycines as aldose reductase inhibitors
US5292935A (en) Method of synthesis and novel compounds for pharmaceutical uses
SK319892A3 (en) N-phenyl-2-cyano-3-hydroxycrotonamide derivatives, method of their poduction and their using for manufacture of medicines with immunomodulating effect
PT86677B (pt) Processo para a preparacao de cinolina-carboxamidas e de composicoes farmaceuticas que as contem
DE19930075A1 (de) Neue Amino- und Amidosulfonamide als antivirale Mittel
JP3003941B2 (ja) 新規なｎ―〔置換アリール〕―ｎ’―〔置換アルコキシ〕―尿素およびチォ尿素誘導体
US4233310A (en) Antiarteriosclerotic N-(mercaptoacyl)-histidines
AU777602B2 (en) An improving agent for hypoalbuminaemia
JPS61286359A (ja) Ｎ−〔〔５−（トリフルオロメチル）−６−メトキシ−１−ナフタレニル〕チオキソメチルまたはカルボニル〕−ｎ−メチルグリシンアミド
US5116857A (en) Method of increasing gastrointestinal motility with substituted benzamides
US4514390A (en) Melaminylthioarsenites
US4923896A (en) N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US5475028A (en) 2-aminoethanesulfonic acid zinc complex
SU940645A3 (ru) Способ получени производных 1,1 @ -бифенил-2-илалкиламина
US3420882A (en) Benzenesulfonyl ureas
JPS6322565A (ja) アルド−スレダクタ−ゼ抑制剤として有用なナフタレニルスルホニルイミダゾリジンジオンおよびそのチオキソ類似体
US3308019A (en) Alkyl-n-[alpha, alpha-dimethyl-beta-(p-halophenyl)-ethyl]-carbamates and compositions thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988906435

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988906435

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988906435

Country of ref document: EP